SI2949658T1 - Peptides that specifically bind HGF receptor (cMet) and uses thereof - Google Patents

Peptides that specifically bind HGF receptor (cMet) and uses thereof

Info

Publication number
SI2949658T1
SI2949658T1 SI200432448T SI200432448T SI2949658T1 SI 2949658 T1 SI2949658 T1 SI 2949658T1 SI 200432448 T SI200432448 T SI 200432448T SI 200432448 T SI200432448 T SI 200432448T SI 2949658 T1 SI2949658 T1 SI 2949658T1
Authority
SI
Slovenia
Prior art keywords
cmet
peptides
uses
specifically bind
hgf receptor
Prior art date
Application number
SI200432448T
Other languages
Slovenian (sl)
Inventor
Aaron K. Sato
Daniel T. Dransfield
Robert C. Ladner
Original Assignee
Dyax Corp.
Bracco Suisse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US45158803P priority Critical
Application filed by Dyax Corp., Bracco Suisse Sa filed Critical Dyax Corp.
Priority to EP15157779.8A priority patent/EP2949658B1/en
Publication of SI2949658T1 publication Critical patent/SI2949658T1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group the fluorescent group being a small organic molecule
    • A61K49/0041Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043Fluorescein, used in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056Peptides, proteins, polyamino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/4753Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
SI200432448T 2003-03-03 2004-03-03 Peptides that specifically bind HGF receptor (cMet) and uses thereof SI2949658T1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US45158803P true 2003-03-03 2003-03-03
EP15157779.8A EP2949658B1 (en) 2003-03-03 2004-03-03 Peptides that specifically bind HGF receptor (cMet) and uses thereof

Publications (1)

Publication Number Publication Date
SI2949658T1 true SI2949658T1 (en) 2018-10-30

Family

ID=32962606

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200432448T SI2949658T1 (en) 2003-03-03 2004-03-03 Peptides that specifically bind HGF receptor (cMet) and uses thereof

Country Status (11)

Country Link
US (6) US20050214859A1 (en)
EP (4) EP1603935A4 (en)
JP (4) JP5466350B2 (en)
AU (2) AU2004217894B2 (en)
CA (1) CA2517939C (en)
DK (2) DK2284180T3 (en)
ES (3) ES2692166T3 (en)
HU (1) HUE039154T2 (en)
PL (1) PL2949658T3 (en)
SI (1) SI2949658T1 (en)
WO (1) WO2004078778A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008844A1 (en) * 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
SI2949658T1 (en) * 2003-03-03 2018-10-30 Dyax Corp. Peptides that specifically bind HGF receptor (cMet) and uses thereof
US20080261233A1 (en) 2004-10-20 2008-10-23 Peas Institut Ab Assessment of Biological Activity of Hepatocyte Growth Factor (Hgf)
US8236761B2 (en) 2006-07-07 2012-08-07 Washington State University Research Foundation C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
WO2008005531A2 (en) * 2006-07-07 2008-01-10 Washington State University Research Foundation C-met receptor regulation by angiotensin iv (at4) receptor ligands
US8389482B2 (en) 2007-01-30 2013-03-05 New York University Short peptides useful for treatment of ischemia/reperfusion injury and other tissue damage conditions associated with nitric oxide and its reactive species
CA2685553C (en) 2007-05-16 2017-03-28 Ge Healthcare As Peptide imaging agents
GB0718967D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0718957D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
GB0918321D0 (en) 2009-10-20 2009-12-02 Ge Healthcare As Cyclic peptide synthesis
US9075059B2 (en) 2009-11-05 2015-07-07 University Of Virginia Patent Foundation Compositions and methods for detecting plectin-1 as a biomarker for cancer
GB201013808D0 (en) * 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201116733D0 (en) 2011-09-28 2011-11-09 Ge Healthcare As Peptide margin imaging agents
GB201116862D0 (en) 2011-09-30 2011-11-09 Ge Healthcare As Infusion imaging method
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
WO2014074907A1 (en) * 2012-11-09 2014-05-15 Indi Molecular, Inc. C-met-specific capture agents, compositions, and methods of using and making
CN105209054A (en) 2013-04-18 2015-12-30 阿尔莫生物科技股份有限公司 Methods of using interleukin-10 for treating diseases and disorders
EP3010527B1 (en) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
WO2015026423A1 (en) 2013-08-20 2015-02-26 Infusion Medical, Inc. Syringe fill system and method
JP6509867B2 (en) 2013-08-30 2019-05-08 アルモ・バイオサイエンシーズ・インコーポレイテッド Methods of using interleukin-10 to treat diseases and disorders
SG11201602870YA (en) 2013-10-28 2016-05-30 Ngm Biopharmaceuticals Inc Cancer models and associated methods
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
EP3180431A1 (en) * 2014-08-11 2017-06-21 Miti Biosystems GmbH Cyclic peptides expressed by a genetic package
WO2016049044A1 (en) * 2014-09-22 2016-03-31 National Health Research Institutes Use of 5-methoxytryptophan as diagnostic agent of inflammatory diseases
JP2017536098A (en) 2014-10-14 2017-12-07 アルモ・バイオサイエンシーズ・インコーポレイテッド Interleukin-15 composition and use thereof
EP3209320A4 (en) 2014-10-22 2018-07-18 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP2018516913A (en) 2015-05-28 2018-06-28 アルモ・バイオサイエンシーズ・インコーポレイテッド Pegylated interleukin-10 for use in cancer therapy
WO2016196211A1 (en) 2015-05-29 2016-12-08 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
CN109563144A (en) * 2016-06-01 2019-04-02 M3生物技术公司 Compound
US20190151483A1 (en) 2016-07-25 2019-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods of making 18f-labeled precursors and peptides, labeled c-met binding peptides, and methods of use thereof
JPWO2018052002A1 (en) * 2016-09-13 2019-08-22 第一三共株式会社 Thrombospondin 1 binding peptide

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4391797A (en) 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
DE3313946A1 (en) 1983-04-15 1984-10-18 Schering Ag Microparticles and gasblaeschen-containing ultrasound contrast agents
DE3313947A1 (en) 1983-04-15 1984-10-18 Schering Ag Microparticles and gasblaeschen-containing ultrasound contrast agents
US4900540A (en) 1983-06-20 1990-02-13 Trustees Of The University Of Massachusetts Lipisomes containing gas for ultrasound detection
US4899755A (en) 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
MX174467B (en) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboxymethyl-1,4,7,10-decane substituted tetraazaciclodo 1 and analogous compounds
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US4844882A (en) 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
IE61591B1 (en) 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE3834705A1 (en) 1988-10-07 1990-04-12 Schering Ag microparticles ultrasound contrast agents from gasblaeschen and fatty acid-containing
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
WO1991003200A1 (en) 1989-08-28 1991-03-21 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic nmr imaging
US5118797A (en) 1989-08-28 1992-06-02 E. R. Squibb & Sons, Inc. Rhenium tris dioxime complexes
US5123414A (en) 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5773024A (en) 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5230882A (en) 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5871959A (en) * 1989-12-27 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Method of producing hepatocycte growth factor/scatter factor and related cell lines
CA2034042C (en) 1990-01-18 1999-08-17 Adrian D. Nunn Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group
US5578292A (en) 1991-11-20 1996-11-26 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
IN172208B (en) 1990-04-02 1993-05-01 Sint Sa A method of preparing a composition adapted for injection into the blood stream and body cavities of living beings
US5183653A (en) 1990-04-13 1993-02-02 E. R. Squibb & Sons, Inc. Boronic acid adducts of metal dioxime complexes useful in labelling proteins and other amine-containing compounds
US5137928A (en) 1990-04-26 1992-08-11 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
US5173298A (en) 1990-09-27 1992-12-22 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
ES2141102T3 (en) 1991-02-08 2000-03-16 Diatide Inc Polypeptides labeled with technetium-99m for imaging.
US5849261A (en) 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
DE69232718T2 (en) 1991-02-22 2003-04-03 American Cyanamid Co Identification of a human receptor tyrosine kinase gene
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
GB9106686D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
DE69219331T3 (en) 1991-06-03 2001-06-07 Nycomed Imaging As Improvements in relation to contrast agents
JPH06510758A (en) 1991-07-05 1994-12-01
US5808091A (en) 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
GB9200388D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200391D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200387D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5316921A (en) * 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants
DE69332221T2 (en) * 1992-05-18 2003-04-17 Genentech Inc Hepatozytwachstumfaktor variant
KR957003064A (en) * 1992-08-10 1995-08-23 그레고리비. 버틀러 Inhibition of cell growth materials, methods, methods of producing and using
CA2435503C (en) 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
EP1238986B1 (en) 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
WO1995001187A1 (en) 1993-07-02 1995-01-12 Molecular Biosystems, Inc. Protein encapsulated insoluble gas microspheres and their preparation and use as ultrasonic imaging agents
AT162524T (en) 1993-07-19 1998-02-15 Resolution Pharm Inc Hydrazine with a N3S configuration as radionuclide chelators
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
US5574140A (en) 1993-09-03 1996-11-12 Resolution Pharmaceutical Inc. Hydrazino-type N2 S2 chelators
PL182223B1 (en) 1993-12-15 2001-11-30 Bracco Research Sa Usg contrast medium
GB9402867D0 (en) 1994-02-15 1994-04-06 Nycomed Imaging As Improvements in or relating to contrast agents
DE69434538T2 (en) 1994-03-08 2006-08-10 Human Genome Sciences, Inc. Vascular Endothelial Growth Factor 2
JP2891647B2 (en) 1994-03-11 1999-05-17 株式会社日本触媒 Organic sulfide compound and a method of manufacturing the same
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5582814A (en) 1994-04-15 1996-12-10 Metasyn, Inc. 1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging
CA2188292A1 (en) 1994-04-20 1995-11-02 Larry Margerum Contrast agents
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5662885A (en) 1994-07-22 1997-09-02 Resolution Pharmaceuticals Inc. Peptide derived radionuclide chelators
GB9417941D0 (en) 1994-09-06 1994-10-26 Nycomed Imaging As Improvements in or relating to contrast agents
US5556939A (en) 1994-10-13 1996-09-17 Merck Frosst Canada, Inc. TC or RE radionuclide labelled chelate, hexapeptide complexes useful for diagnostic or therapeutic applications
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
DE4445065A1 (en) 1994-12-07 1996-06-13 Diagnostikforschung Inst A method for in vivo diagnostics by means of NIR-radiation
IL116328A (en) 1994-12-16 1999-09-22 Bracco Research Sa Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging
TW319763B (en) 1995-02-01 1997-11-11 Epix Medical Inc
GB9502065D0 (en) 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
EP1444991A1 (en) 1995-06-07 2004-08-11 Imarx Pharmaceutical Corp. Novel targeted compositions for diagnostic and therapeutic use
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
DE69628652D1 (en) 1995-09-08 2003-07-17 Genentech Inc Vegf-related protein
AU1116297A (en) 1995-11-08 1997-05-29 Immunex Corporation Flk-1 binding protein
US5837680A (en) 1996-02-16 1998-11-17 Children's Medical Center Corporation Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis
EP0881915B1 (en) 1996-02-19 2003-04-23 Amersham Health AS Improvements in or relating to contrast agents
DE69729380D1 (en) 1996-04-01 2004-07-08 Epix Medical Inc Bio-activated diagnostic image generation contrast agent
IL128345D0 (en) 1996-08-02 2000-01-31 Nycomed Imaging As Improvements in or relating to contrast agents
TW320761B (en) * 1996-10-03 1997-11-21 Mos Electronics Taiwan Inc Manufacturing method of high density DRAM with cylindrical stack capacitor
HU224218B1 (en) 1996-10-21 2005-06-28 Amersham Health As Improved contrast agents
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
WO1998018495A2 (en) 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
NZ335596A (en) 1996-10-28 2000-10-27 Nycomed Imaging As Diagnostic and therapeutic agents comprising microbubbles of a reporter, a surfactant and a vector
EP0973552B1 (en) 1996-10-28 2006-03-01 Amersham Health AS Improvements in or relating to diagnostic/therapeutic agents
WO1998018496A2 (en) 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
EP0946202B1 (en) 1996-10-28 2003-09-10 Amersham Health AS Contrast agents
WO1998018498A2 (en) 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
US5919967A (en) 1997-04-11 1999-07-06 Epix Medical, Inc. Process for synthesizing phosphodiesters
DE19717904A1 (en) 1997-04-23 1998-10-29 Diagnostikforschung Inst Acid labile and enzymatically cleavable dye constructs for diagnosis with near-infrared light and for therapy
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
US6245318B1 (en) 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion Transdermal delivery system
GB9712525D0 (en) 1997-06-16 1997-08-20 Nycomed Imaging As Method
ES2292204T3 (en) 1997-06-18 2008-03-01 MERCK & CO., INC. (A NEW JERSEY CORP.) Human receptor tyrosine kinase KDR.
PT1019094E (en) 1997-10-02 2004-03-31 Epix Medical Inc Method of diagnosis by imagiology with intensified contrast for monitoring of intervention therapies
EP1037994A1 (en) 1997-12-09 2000-09-27 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
US6165458A (en) 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
AU753196B2 (en) 1998-02-09 2002-10-10 Bracco Research S.A. Targeted delivery of biologically active media
WO1999040947A2 (en) 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
SK13952000A3 (en) 1998-03-31 2001-12-03 Dupont Pharmaceuticals Company Pharmaceuticals for the imaging of angiogenic disorders
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
EP1126842A2 (en) 1998-11-06 2001-08-29 Basf Aktiengesellschaft Inhibition of the formation of vascular hyperpermeability
US6312665B1 (en) 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
AU3517000A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. 50 human secreted proteins
EP1169344A1 (en) * 1999-03-12 2002-01-09 Human Genome Sciences, Inc. 47 human secreted proteins
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
GB9928950D0 (en) 1999-12-07 2000-02-02 Metris Therapeutics Limited Binding protein
EP1248642A4 (en) 2000-01-18 2005-05-18 Ludwig Inst Cancer Res Vegf-d/vegf-c/vegf peptidomimetic inhibitor
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
CA2399022A1 (en) 2000-02-04 2001-08-09 Supratek Pharma Inc. Ligand for vascular endothelial growth factor receptor
AU3988401A (en) 2000-02-25 2001-09-03 Ludwig Inst Cancer Res Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
JP2003525248A (en) 2000-03-02 2003-08-26 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Treatment of cancers expressing vascular endothelial growth factor d, screening and detection methods
US20020102260A1 (en) 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
US6769080B2 (en) * 2000-03-09 2004-07-27 Texas Instruments Incorporated Scan circuit low power adapter with counter
US20010031485A1 (en) 2000-03-22 2001-10-18 Sibtech, Inc. Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
JP2003527441A (en) 2000-03-22 2003-09-16 グラクソ グループ リミテッド Medicament comprising an agent and an antibody to block cell cycle
US20050019826A1 (en) 2000-03-31 2005-01-27 Roselyne Tournaire Peptides blocking vascular endothelial growth factor(vegf)-mediated angiogenesis, polynucleotides encoding said pepetides and methods of use thereof
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
AU5919501A (en) 2000-04-28 2001-11-12 Glaxo Group Ltd Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
US6689352B2 (en) 2000-05-03 2004-02-10 Ludwig Institute For Cancer Research Method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
KR100457350B1 (en) * 2000-06-01 2004-11-16 이경림 IgE-dependent histamine-releasing factor(HRF) receptor, HRF-binding peptides and nucleic acids encoding the same, and uses thereof
EP1166798A1 (en) 2000-06-23 2002-01-02 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use
AU784231B2 (en) 2000-06-23 2006-02-23 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use (II)
EP1166799A1 (en) 2000-06-28 2002-01-02 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)
AU7693401A (en) 2000-07-18 2002-02-05 Joslin Diabetes Center Inc Methods of modulating fibrosis
US20020091082A1 (en) 2000-09-13 2002-07-11 Aiello Lloyd P. Methods of modulating symptoms of hypertension
FR2814744B1 (en) * 2000-10-04 2002-11-29 Commissariat Energie Atomique Cyclopeptides, their process for the preparation and their use as an inhibitor or activator of angiogenesis
AU2002362461A1 (en) 2001-10-01 2003-04-14 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
US20030082103A1 (en) 2000-10-11 2003-05-01 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
US20030176674A1 (en) 2001-04-13 2003-09-18 Rosen Craig A. Vascular endothelial growth factor 2
WO2003000842A2 (en) * 2001-06-04 2003-01-03 Curagen Corporation Novel proteins and nucleic acids encoding same
CA2450921A1 (en) * 2001-06-22 2003-01-03 Incyte Genomics, Inc. Protein modification and maintenance molecules
US6766860B2 (en) * 2002-02-22 2004-07-27 Globalsantafe Corporation Multi-activity offshore drilling facility having a support for tubular string
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
WO2003094617A2 (en) 2002-05-06 2003-11-20 Genentech, Inc. Use of vegf for treating bone defects
SI2949658T1 (en) 2003-03-03 2018-10-30 Dyax Corp. Peptides that specifically bind HGF receptor (cMet) and uses thereof
AU2006321613B2 (en) * 2005-12-09 2012-01-12 Bracco Suisse S.A. Targeting vector-phospholipid conjugates
CA2923248A1 (en) * 2008-02-25 2009-09-03 Nestec S.A. Methods for detecting truncated receptors
US9801473B2 (en) 2012-09-13 2017-10-31 Kids Ii, Inc. Play yard with removable liner
EP3020171B1 (en) 2013-07-12 2017-12-20 Telefonaktiebolaget LM Ericsson (publ) Method for enabling control of data packet flows belonging to different access technologies

Also Published As

Publication number Publication date
US8044175B2 (en) 2011-10-25
WO2004078778A2 (en) 2004-09-16
US20050214859A1 (en) 2005-09-29
DK2949658T3 (en) 2018-10-01
AU2004217894A1 (en) 2004-09-16
JP2017019787A (en) 2017-01-26
ES2692166T3 (en) 2018-11-30
EP1944312B1 (en) 2012-06-27
EP2949658A3 (en) 2016-01-13
ES2557286T3 (en) 2016-01-25
AU2004217894B2 (en) 2010-07-15
EP1603935A4 (en) 2007-03-21
US20110311446A1 (en) 2011-12-22
CA2517939A1 (en) 2004-09-16
ES2396368T3 (en) 2013-02-21
HUE039154T2 (en) 2018-12-28
PL2949658T3 (en) 2018-11-30
EP2949658B1 (en) 2018-08-08
US20100260672A1 (en) 2010-10-14
CA2517939C (en) 2015-11-24
WO2004078778A3 (en) 2004-11-18
EP2949658A2 (en) 2015-12-02
JP2011037872A (en) 2011-02-24
JP6216280B2 (en) 2017-10-18
JP2014159434A (en) 2014-09-04
AU2010235865A1 (en) 2010-11-11
DK2284180T3 (en) 2015-12-21
AU2010235865B2 (en) 2012-11-15
JP5876644B2 (en) 2016-03-02
JP6374913B2 (en) 2018-08-15
JP5466350B2 (en) 2014-04-09
EP1603935A2 (en) 2005-12-14
EP1944312A1 (en) 2008-07-16
EP2284180B1 (en) 2015-09-09
EP2284180A2 (en) 2011-02-16
US20120039802A1 (en) 2012-02-16
JP2007524598A (en) 2007-08-30
US20100261875A1 (en) 2010-10-14
US9000124B2 (en) 2015-04-07
EP2284180A3 (en) 2011-10-05
US9845340B2 (en) 2017-12-19
US20150218218A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
DK1680443T3 (en) Stabilized alpha-helix peptides and uses thereof
TWI356064B (en) Antibodies that bind interleukin-4 receptor
GB2401547B (en) Particulate materials
ME02332B (en) Antigen binding molecules with increased Fc receptor binding affinity and effector function
AU2002238052A1 (en) Antibodies that bind both bcma and taci
HK1117763A1 (en) Sp35 antibodies and uses thereof sp35
SI1711207T1 (en) Interferon alpha antibodies and their uses
ZA200507350B (en) Cannabinoid receptor ligands and uses thereof
ZA200508568B (en) Cannabinoid receptor ligands and uses thereof
IL172026D0 (en) Cannabinoid receptor ligands and uses thereof
EP1802588A4 (en) Substituted amino-pyrimidones and uses thereof
IL157705D0 (en) Igf antagonist peptides
EP1824796A4 (en) Protein scaffolds and uses thereof
ZA200409740B (en) Therapeutic epitopes and uses thereof
GB0405637D0 (en) Protein
HK1092481A1 (en) Polypeptides having binding affinity for her2
GB0324368D0 (en) Polypeptides including modified constant regions
HK1142272A1 (en) Specific binding proteins and uses thereof
ZA200509971B (en) Peptides that bind to the erythropoietin receptor
PL377119A1 (en) Tacis and br3 polypeptides and uses thereof
IL214325A (en) Anti-cmet antibody, composition comprising it and use thereof
IL166442D0 (en) Probiotics for gut neuromuscular functions
AP200704034A0 (en) Polypeptides sthat bind br3 and uses thereof
IL178885D0 (en) Mutant pneumolysim proteins
EP1685152A4 (en) Il-18 binding proteins